Watson Wins U.S. Approval for New Prostate Treatment (Update1) for New Prostate Treatment (Update1)
October 10th, 2008 Posted in prostate relatedWatson Pharmaceuticals Inc. won U.S. approval to sell a prostate enlargement treatment as the drugmaker expands beyond manufacturing generic medicines.
The Food and Drug Administration cleared the once-a-day pill Rapaflo, Watson said today in a statement on PR NewsWire. The drug is designed to reduce symptoms of an enlarged prostate, including urinary pain and resistance. The condition affects most U.S. men in their 60s and as many as 90 percent by age 85, according to the company.